<unk>  is approved for the treatment of hormone-responsive cancers including prostate cancer and premenopausal breast cancer, sex hormone-dependent uterine diseases including endometrial hyperplasia, endometriosis, and uterine fibroids, and in assisted reproduction for female infertility. It is also used off-label for the treatment of precocious puberty, as a puberty blocker in transgender children, and as a component of transgender hormone therapy. In ovulation induction,<unk>  is used for pituitary suppression as an adjunct to gonadotropin administration. It has also been assessed as a nasal spray for use as a hormonal contraceptive in women, with a 96% anovulation rate. Dosages For prostate cancer, the dosage of<unk>  by subcutaneous injection is 500 μg three times per day (once every 8 hours, 1,500 μg/day total) for one week and then 200 μg once daily thereafter. If<unk>  is used as a nasal spray, the dosage for prostate cancer is 800 μg sprayed into the nostrils three times per day (once every 8 hours, 2,400 μg/day total) for one week followed by 400 μg sprayed into the nostrils three times per day (once every 8 hours, 1,200 μg/day total) thereafter. For endometriosis,<unk>  is used specifically as a nasal spray and the dosage is the same as that used for prostate cancer. These dosages of<unk>  for both subcutaneous injection and nasal spray have been found to decrease testosterone levels to near-castrate levels in men with prostate cancer, although suppression was more complete with subcutaneous injection presumably due to suboptimal absorption with intranasal administration. Available forms<unk>  is available in the form of a 1 mg/mL solution for use as a nasal spray or subcutaneous injection once every 8 hours (three times per day) and as 6.3 mg and 9.45 mg implants for subcutaneous injection once every two and three months, respectively.
Buserelin
Goserelin
Gestodene
Fosfestrol
Dimestrol
Dienestrol
Hexestrol
Allenestrol